Welcome to our dedicated page for APIMEDS PHARMACEUTICALS US SEC filings (Ticker: APUS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on APIMEDS PHARMACEUTICALS US's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into APIMEDS PHARMACEUTICALS US's regulatory disclosures and financial reporting.
Apimeds Pharmaceuticals US, Inc. reported interim results showing a May 12, 2025 IPO that sold 3,375,000 shares at $4.00 per share, generating net proceeds of approximately $11.9 million after underwriting discounts, offering expenses and the value of Advisor/Placement Agent warrants. Cash balances plus IPO proceeds are stated to be sufficient to fund operations for at least twelve months from the condensed financial statements issuance date. Shares outstanding increased to 12,575,983 at June 30, 2025 from 7,903,850 at December 31, 2024, reflecting the IPO and conversions of convertible notes. The company recognized stock-based compensation including $1.7 million in fully vested stock grants and stock option expense of $192,053. Advisor and placement agent warrants were recorded as liabilities or reductions to additional paid-in capital with remeasurement activity of $9,518. Convertible notes and promissory notes were amended, converted, or extended, and certain related-party financing activity is disclosed.
FAQ
What is the current stock price of APIMEDS PHARMACEUTICALS US (APUS)?
What is the market cap of APIMEDS PHARMACEUTICALS US (APUS)?
